Bone · 2026
Exogenous vitamin C regulates osteoclast differentiation kinetics, cytoskeletal maturation, and bone resorption through ERK1/2-DAPK1-caspase-3 signaling.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chiang Chen Hao, Huang Cian-Ci, Ma Yi-Shing, Wu Yu-Ting, Kuo Chia-Hsia, Wei Yau-Huei, Chen Chuan-Mu, Liou Ying-Ming
Аннотация
BACKGROUND: Vitamin C (VC) plays essential but incompletely defined roles in osteoclast (OC) development. We examined how exogenous VC and AKR1A-dependent endogenous VC regulate OC differentiation, cytoskeletal organization, resorptive activity, and apoptosis.
METHODS: Murine bone marrow-derived macrophages (BMDMs) from wild-type and AKR1A-deficient mice, together with RAW264.7 cells, were used to assess the effects of exogenous and endogenous VC on OC differentiation, actin ring formation, resorption, apoptotic signaling, and ERK1/2 activation.
RESULTS: AKR1A1 deficiency altered osteoclastogenic kinetics, delaying early differentiation, impairing actin ring formation and early resorption, yet promoting late accumulation of large multinucleated OCs. VC exhibited stage-dependent effects: it was required to initiate osteoclastogenesis but, when supplemented at later stages, suppressed OC maturation and enhanced apoptosis. In both primary cells and RAW264.7 cultures, VC dose-dependently promoted peripheral F-actin ring assembly and increased matrix resorption. Mechanistically, VC enhanced ERK1/2 phosphorylation in mature OCs, selectively increased reactive oxygen species, and activated the DAPK1-caspase-3 axis, including nuclear localization of phospho-DAPK1 and cleaved caspase-3. Pharmacologic ERK inhibition suppressed OC formation and resorptive function.
CONCLUSION: VC acts as a stage-dependent modulator of OC fate, linking ERK1/2-associated cytoskeletal maturation and resorptive activity to DAPK1-caspase-3-mediated apoptotic termination during bone remodeling.
METHODS: Murine bone marrow-derived macrophages (BMDMs) from wild-type and AKR1A-deficient mice, together with RAW264.7 cells, were used to assess the effects of exogenous and endogenous VC on OC differentiation, actin ring formation, resorption, apoptotic signaling, and ERK1/2 activation.
RESULTS: AKR1A1 deficiency altered osteoclastogenic kinetics, delaying early differentiation, impairing actin ring formation and early resorption, yet promoting late accumulation of large multinucleated OCs. VC exhibited stage-dependent effects: it was required to initiate osteoclastogenesis but, when supplemented at later stages, suppressed OC maturation and enhanced apoptosis. In both primary cells and RAW264.7 cultures, VC dose-dependently promoted peripheral F-actin ring assembly and increased matrix resorption. Mechanistically, VC enhanced ERK1/2 phosphorylation in mature OCs, selectively increased reactive oxygen species, and activated the DAPK1-caspase-3 axis, including nuclear localization of phospho-DAPK1 and cleaved caspase-3. Pharmacologic ERK inhibition suppressed OC formation and resorptive function.
CONCLUSION: VC acts as a stage-dependent modulator of OC fate, linking ERK1/2-associated cytoskeletal maturation and resorptive activity to DAPK1-caspase-3-mediated apoptotic termination during bone remodeling.